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Objective: To study the change of the peripheral blood immune pattern and its corre-
lation with prognosis in patients with liver cancer after treated by sorafenib.
Methods: Patients with advanced liver cancer admitted in our hospital were enrolled and
treated with sorafenib. After two months of the treatment, their peripheral blood was
collected. The immune cell subset and cytokines level were determined by ﬂow
cytometry and luminex technology. According to the reaction expressed by patients to-
wards sorafenib, patients were divided into the response group and the no response group.
The changes of the peripheral blood immune pattern and its correlation with prognosis of
patients in the two groups were compared.
Results: Before and after treatment of sorafenib, there was no signiﬁcant difference in
the ratios of T cells, NK cells and their subtypes in peripheral blood of patients between
the two groups; while after treatment the ratio of B cells and regulatory B cells (Breg) of
patients in the response group was signiﬁcant higher than that of the no response group
(P < 0.05), and the prognosis conditions of patients with decreased ratio of Breg cells
were better than other patients after undergoing chemotherapy. The levels of plasma
cytokines IL-6, IL-10, IL-12, IL17, FIL-3L, IFN-g, TNF-a, MCP-1 and VEGF showed
no signiﬁcant differences.
Conclusions: After treatment of sorafenib, the prognosis conditions of patients of
advanced liver cancer with a reduced Breg ratio are better than patients with an unaltered
or increased Breg ratio. The ratio of Breg in peripheral blood may be considered as early
biological indicator for the prediction of the curative effects of sorafenib.1. Introduction
Liver cancer is one of the commonest malignant tumors in
our country with a appropriate incidence rate of 1/10000 and
more than 600000 new added cases each year in the world,which has a strong impact on mankind's health and life quality
[1,2]. The detection rate of early liver cancer is about 30%–40%
[3]. The majority of advanced liver cancer patients are not
suitable for radical resection and liver transplantation. In short
of effective treatment measures, patients live with a short
survival period and poor prognosis [4–6]. Sorafenib is the ﬁrst
ﬁrst-line drug which was approved to be applied in the sys-
tematic treatment of liver cancer. Many domestic and abroad
clinical researches have proved that sorafenib can prolong the
survival period of patients with advanced liver cancer and slow
the development of cancer [3,7–10]. However, sorafenib do not
work for all liver cancer patients [11]. The reason remains to
be further studied. Multiple studies reveal that chemotherapy
can inﬂuence the immune system of cancer patients [12–14].
Then, dose the change of the immune pattern inﬂuence theticle under the CC BY-NC-ND license (http://
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of the immune pattern and its correlation with prognosis in
patients with advanced liver cancer after treated by sorafenib
by testing their immune patterns.
2. Materials and methods
2.1. Materials
Lymphocyte separation medium with a concentration of
1.077 used in this study was purchased from Sinopharm
Chemical Group. Flow antibodies, cell ﬁxed liquid and trans-
membrane liquid, such as human CD3 (marked by FITC), CD4
(marked by PE), CD8 (marked by PB), CD56 (marked by APC),
CD25 (marked by APC-Cy7), CD27 (marked by APC-Cy7),
CD19 (marked by PE), CD24 (marked by PE) and Foxp3
(marked by APC) were all bought from eBioscience Company.
Human cytokines, Milliplex kits and Luminex 200 detection
system were all from Millipore.
2.2. Methods
2.2.1. Clinical materials
A total of 73 advanced liver cancer patients who were
treated in our hospital from September 2013 to March 2015
were selected and treated with sorafenib. Among them, ﬁve
quitted the study due to severe adverse reactions, four cases did
not return for further consultation and peripheral blood
collection at the fourth week after using drugs, two lost to
follow-up. Therefore, a total of 62 cases were included in
statistical analysis of this study. Among those included pa-
tients, 41 cases were males and 21 cases were females; 24 cases
were under 45 years old and 38 cases were over 45 years; 18
cases underwent surgical treatment while 44 cases did not; 37
cases suffered from metastasis, while 25 cases did not; alpha
fetoprotein (AFP) was less than 50 in 14 cases; while it was
more than 50 in 44 cases, 9 of which were caused by hepatitis
C, 13 by excessive drinking, 12 by hepatitis B and the cause of
the other 28 cases remained unknown. All patients were
diagnosed as advanced liver cancer by pathology examination
(could not accept surgical treatment or reoccurred after surgical
and local treatment) with good liver, renal and hematopoietic
functions. Patients received systemic anti-cancer treatment and
patients with liver, renal and hematopoietic dysfunctions were
excluded. All patients signed an informed consent. The study
was approved by the Ethical Inspection Committee of our
hospital.
2.2.2. Chemotherapy scheme and therapeutic effect
evaluation
Patients met the inclusion criteria were treated with sorafenib
orally 400 mg a time once every two days. Four cases showed
severe side effects (hand and foot skin reaction, lipsotrichia,
rash, diarrhea and hypertension) which did not involved in sta-
tistics. Therapeutic effect evaluation was conducted every three
weeks after using drugs. The evaluation standard consulted the
Response Evaluation Criteria in Solid Tumors (RECIST) [15].
2.2.3. Flow cytometry
Anticoagulant tube was used to collect 5 mL peripheral
blood of advanced liver cancer patients before and 4 weeksafter treatment, respectively. Peripheral blood mononuclear
cells (PBMC) were isolated by lymphocytes separating solu-
tion and then the upper serum was collected and stored
at −80 C. PBMC were suspended again after washed by PBS
with a regulated concentration of 1 × 106/mL. After blocked,
ﬂow antibodies were added for dying. And it was incubated in
a cool dark place at 4 C for 30 min and then detected after
washed by PBS twice. Intracellular dyed cells incubated anti-
bodies after treated by ﬁxed transmembrane liquid. They were
tested after washing by transmembrane liquid. The ﬂow results
were determined by BD FACS Calibur and analyzed by
FlowJo software. Isotype control antibody-dyed cells were
used as the negative control in the analysis of ﬂow results.
Surface markers such as CD3, CD4, CD8, CD25/Foxp3 and
CD45RA/CD45RO were used to illustrate T cell subset, CD19
and CD24/CD25 were to analyze B cells, and CD56 was to
mark NK cells.
2.2.4. Luminex
Plasma collected from patients with liver cancer was
stored in the refrigerator at −80 C and was not thawed and
refrozen before detection. Milliplex kits and the corre-
sponding Luminex 200 liquidchip system (Millipore) were
applied to detect the levels of IL-6, IL-10, IL-12, IL17, FIL-
3L, IFN-g, TNF-a, MCP-1 and VEGF of plasma in patients.
The operation procedure was strictly followed the con-
structions. Firstly, 25 mL diluent, 25 mL plasma and 25 mL
mierospheres were mixed and added onto 96-well plates for
incubation overnight. Then, after washed, 25 mL detected
antibodies were added and incubated for 30 min. After that,
25 mL streptavidin-phycoerythrin was added in after
rewashed and again incubated for 30 min. Next, the plate
was washed twice. Mierospheres were suspended on 100 mL
sheath ﬂuid and detected and analyzed by Luminex 200.
The concentration of each cytokine was counted on a basis
of the mean ﬂuorescence intensity (MFI).
2.2.5. Statistical analysis
All data in this study were counted and analyzed by
Graphpad Prism 4.0. The comparison between immune cell
subset and cytokines of patients before and after treatment were
tested with t-test. Means between two groups were analyzed by
Student's t-test. Differences remained to be statistically signiﬁ-
cant when P < 0.05. Measurement data were expressed by
mean ± SD.3. Results
3.1. Treatment outcomes
In this study, a total of 62 patients were included, of which 41
were males and 21 were females. A follow-up of these patients
was conducted after they were treated by sorafenib and the last
follow-up was done on January 2016. The median survival time
was 10.2 months, median progression free survival time was 3.9
months, and 22 patients survived. After treatment, 4 cases
showed slight side effects which was lessened after symptomatic
treatment. The effective rate reached 71% after patient were
treated by sorafenib. The illness of 44 patients were controlled
(42 cases were in stable conditions and 2 cases were in remis-
sion). Those patients were regarded as the response group. The
Table 1
Change in lymphocyte proﬁles in HCC patients following sorafenib
therapy.
Cell type Before (%) After (%)
Response No response Response No response
T cell 68.73 ± 8.21 63.73 ± 10.25 71.78 ± 3.87 67.02 ± 7.19
CD4+ T
cell
51.68 ± 7.22 48.20 ± 7.06 50.21 ± 9.21 47.02 ± 7.83
CD8+ T
cell
23.12 ± 4.06 20.87 ± 5.28 24.77 ± 5.01 22.80 ± 3.05
Regulatory
T cell
4.01 ± 0.65 5.56 ± 1.05 4.76 ± 0.33 6.28 ± 0.97
Memory T
cell
43.71 ± 5.07 46.72 ± 4.48 45.08 ± 6.73 46.71 ± 0.52
B cells 7.91 ± 2.11 8.10 ± 1.02 5.23 ± 0.71 9.92 ± 0.70*
Regulatory
B cell
0.81 ± 0.10 1.02 ± 0.13 0.73 ± 0.11 1.91 ± 0.26*
NK 18.73 ± 3.10 20.09 ± 2.50 19.21 ± 3.22 21.04 ± 3.81
*: Compared with the response group, P < 0.05.
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were included in the no response group.
3.2. The distribution of peripheral blood immune cell
subset of patients before and after treatment
The ratios of peripheral blood T cells, B cells, NK cells and
their subsets of advanced liver cancer patients before and after
treated by sorafenib were detected. The ratios of total T cells,
CD4+ T cells, regulatory T cells, memory T cells and NK cells
in the two groups showed no differences; while the ratio of B
cells and regulatory B cells (Breg) in PBMC of patients in the
response group was higher than that of in the no response group
(P < 0.05) (Table 1).
3.3. The correlation of the ratio of Breg cells and
prognosis of patients treated with chemotherapy
In order to further analyze the relationship between Breg cells
and chemotherapy efﬁcacy, according to the change of the Breg
ratios in PBMC in patients before and after chemotherapy, we
divided the subjects in to the Breg-reduced group (the ratio of
Breg decreased more than half as compared with rpe-
chemotherapy, n = 29) and the no Breg-reduced group
(n = 29). The median survival time of patients with increased or
changeless Breg ratios after treated with sorafenib was 9.3 (7.3–
14.0) months, while the median survival time of patients with
induced Breg ratios was 10.6 (9.0–18.2) months. Differences
were statistically signiﬁcant.Table 2
The level of cytokines in serum of HCC patients following sorafenib therap
Cytokines Before (pg/mL)
Response No respons
IL-6 2.04 ± 0.77 3.21 ± 1.6
IL-10 18.39 ± 7.55 8.91 ± 5.0
IL-12 13.17 ± 1.44 11.88 ± 2.0
IL-17 4.82 ± 0.49 3.84 ± 0.6
FIL-3L 24.52 ± 7.41 34.12 ± 11
IFN-g 14.52 ± 2.73 9.77 ± 3.0
TNF-a 4.24 ± 1.53 5.20 ± 1.7
MCP-1 224.01 ± 32.13 197.13 ± 21
VEGF 89.72 ± 11.35 102.3 ± 223.4. The level of cytokines in serum of patients before
and after chemotherapy
Levels of multiple inﬂammatory cytokines including IL-6,
IL-10, IL-12, IL17, FIL-3L, IFN-g, TNF-a, MCP-1 and
VEGF were tested simultaneously by luminex technology. The
results showed that the level of cytokines in serum of patients in
the response and no response groups had no statistical differ-
ences (Table 2).
4. Discussion
Hepatocellular carcinoma is a clinically common cancer in our
country with a pretty high malignant degree, strong wetting
property and transitivity, high recurrence rate and poor prognosis.
Patients dead from liver cancer each year in our country accounts
for about 50% in the total number of the world, which has brought
heavy burdens for our society [16]. At present, for patients with
early liver cancer, surgical treatment of this disease is the ﬁrst
choice. However, it is difﬁcult to diagnose the disease at the
onset. Most patients have reached the locally advanced stage or
gone through distant metastasis and therefore loss the best
surgical time. Thus, the effective treatment of advance liver
cancer is what we clinical workers are confronting.
Sorafenib is the ﬁrst effective molecular target drug in the
world which was approved by FDA and proved to obviously
prolong the survival time of HCC patients, and it is also rec-
ommended to be a ﬁrst-line drug for HCC patients who should
not be treated with surgery [16]. On the one hand, sorafenib can
ﬁght against cancer by inhibiting the activity of Raf kinase of
cancer cells and interdicting the Ras/Raf/MAPK cascade
signal pathway to inhibit the proliferation of cancer cells. On
the other hand, sorafenib can also lower the activities of
angiogenesis factors receptor −2 and −3 and plays a role of
anti-angiogenesis [17,18]. In this study, 62 cases with advanced
liver cancer were treated with sorafenib. Illness of 44 of them
has been controlled (42 cases were in stable conditions and 2
cases were in remission). The effective rate was 71% (44/62).
The total medium survival time was 10.2 (7.3–18.2) months,
which was matched with results of other domestic and abroad
clinical researches [3,19].
More and more evidences have clariﬁed that the immune
state of cancer patients is closely related to the growth and
prognosis of tumors. Researchers have shown that there are
many immune cells inﬁltrating the liver cancer tissues. Besides,
the inﬁltration degree of FoxP3+ Treg and IL-17+ T cells was
negatively correlated with the prognosis of patients [20].
Tumor-related macrophages can promote epithelial andy.
After (pg/mL)
e Response No response
0 2.31 ± 0.59 2.55 ± 0.41
2 7.71 ± 3.02 8.22 ± 2.10
6 14.12 ± 4.75 12.29 ± 2.05
6 5.72 ± 0.61 4.77 ± 0.71
.05 27.08 ± 6.22 43.09 ± 15.21
1 18.87 ± 5.62 9.84 ± 3.06
7 5.62 ± 1.14 6.01 ± 2.83
.70 219.72 ± 26.18 206.96 ± 34.44
.77 98.06 ± 23.83 134.12 ± 31.94
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by transforming growth factors [21]. Tumor-related neutrophils
can recruit Treg to the local tumor to facilitate the growth of
tumor and strengthen its drug resistance [22]. However, due to
the limitation of the speciﬁcity of samples, the inﬁltration
condition of local tumor immune cells can provide no basis
for the treatment of the disease. Therefore, in this study those
advanced liver cancer patients were divided into the response
and no response groups in accordance with the reactions they
had shown after treated by sorafenib to analyze the types of
peripheral blood immune cells and the cytokine level after
they were treated for a month, which aimed to provide early
indexes for the evaluation of prognosis for patients with
chemotherapy and those patients to choose a suitable
therapeutic regimen. It was found that before and after
treated by sorafenib the ratio of T cells and NK cells of
peripheral blood of the two groups had no differences, but
the ratio of B cells and Breg cells of patients in the response
group was signiﬁcantly lower than that in the no response
group (P < 0.05); while the serum cytokines (IL-6, IL-10,
IL-12, IL17, FIL-3L, IFN-g, TNF-a, MCP-1 and VEGF) of
the two groups remained changeless, which indicated that the
levels of these cytokines had little to do with the development
and prognosis of the illness conditions of advanced liver cancer
patients. That is to say they cannot serve as prediction indexes
for the effect of sorafenib in patients with advanced liver
cancer.
As always, it is considered that B cells play immunologic
functions to accelerate inﬂammatory reactions by presenting
antibodies, secreting cytokines and mediating humoral immune
responses [23,24]. Recent studies have found that there is a
series of Breg existing in bodies. Breg is an important B cell
subset which could control immune responses by secreting
IL-10 and transforming growth factor-b1 and other suppres-
sive cytokines [25,26]. There is a research manifesting that the
ratio of Breg in local tumor area of liver cancer patients was
higher than those in the tumor or non-tumor areas; the ratio
of peripheral Breg of liver cancer patients was also higher than
that of health people [27]. The ratio was closely related to
neoplasm staging, tumor diversity and venous invasion. The
research pointed out that Breg could promote the growth and
inﬁltration of liver cancer cells by CD40/CD154 signal
pathway. Our study results also discovered that after treated
with sorafenib, patients with decreased Breg cells ratio lived
longer than those patients whose Breg cell ratio increased.
The above research results showed that the ratio of peripheral
blood Breg cells in advanced liver cancer patients is closely
related to the development and prognosis of the disease. It
can therefore serve as early biological indicator for the
prediction of the curative effect of chemotherapy so as to
provide references for the optimization of the therapeutic
regimen.
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